RecruitingPhase 3NCT07816185

A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)

A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Sponsor

Pulmovant, Inc.

Enrollment

376 participants

Start Date

Aug 31, 2026

Study Type

INTERVENTIONAL

Conditions

Cardiovascular Diseases Fibrosis Interstitial Lung Disease Pulmonary Hypertension Vascular Diseases

Summary

A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Dry Powder Inhaler, a drug called Mosliciguat, and others for people with cardiovascular diseases, fibrosis, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.